Key Contextual Factors
- According to some estimates, there are around 200 different types of rare cancers, including rare adult solid tumours and rare haematological cancers as well as all childhood cancers.
- Rare cancers comprise 24% of the total cancer cases diagnosed every year in the EU (1).
- Despite being rare, pediatric cancers remain the 1st cause of mortality by disease among young people in Europe with 6,000 deaths per year (2).
Key Components/Steps
- Dissemination as peer-reviewed literature (3)
- Update of the information concerning rare cancers in children and AYA (adolescents and young adults) in collaboration with SIOPE (European Society for Pediatric Oncology) (2023-24).
Main Impacts / Added Value
- Rare cancers are hardly addressed in NCCPs. Of the NCCPs examined, 8 considered rare cancers in adults to some extent (10 in the case of children and AYA), while 7 contained no information (5 in the case of children and AYA).
- Due to the rarity of each single cancer disease, rare cancers have a strong European added value as no one country alone can tackle this issue.
- Policies and recommendations based on common EU MS priorities have been developed to address the challenges posed by rare cancers.
Lessons Learned
- Centralising care for patients with rare cancers in reference centres emerges as a necessary condition for effecting change in the organisation of services.
- Care for rare cancers should be based on expert multidisciplinary teams, which should in turn be articulated with other levels of care.
- The possibility of treating a rare cancer (e.g. sarcoma) in one centre should not prevent collaboration with other centres in the case of a pathological subtype (e.g. bone sarcoma).
- Continuity of care is a critical dimension. The health system should manage the possible changes in centres, services and reference professionals derived from patients' changing needs.
- Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493-511.
- International Agency for Research on Cancer. (2018). Cancer Today. Retrieved from Cancer Today website: https://gco.iarc.fr/today/home
- Joan Prades, Ariane Weinman, Yann Le Cam, Annalisa Trama, Anna Maria Frezza, Josep M. Borras. Priorities on rare cancers’ policy in National Cancer Control Plans (NCCPs): A review conducted within the framework of EU-JARC Joint-Action. J Cancer Policy 24 (2020).
References and Documentation
Contact
- Institution/organization: Catalan Health Service Barcelona, Spain
-
Department/lead: Department of Health
- E-mail: jprades@iconcologia.net
- Web: www.catsalut.gencat.cat